Palisade Bio (DB:7NS0) - Aandelenkoers, Nieuws & Analyse

7NS0 Overzicht aandelen

A clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. Meer informatie

7NS0 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 18.7% per jaar dalen.

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

+ 2 meer risico's

Palisade Bio, Inc. Concurrenten

MPH Health Care

DB:93M1

€105.3m

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Palisade Bio
Historische aandelenkoersen
Huidige aandelenkoers	US$5.01
52 Week Hoogtepunt	US$30.82
52 Week Laag	US$4.75
Bèta	1.29
11 maand verandering	0%
3 maanden verandering	0.12%
1 Jaar Verandering	-78.46%
33 jaar verandering	-99.77%
5 jaar verandering	n/a
Verandering sinds IPO	-99.89%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	7NS0	DE Pharmaceuticals	DE Markt
7D	0%	-1.2%	-0.02%
1Y	-78.5%	-20.1%	8.2%

Rendement versus industrie: 7NS0 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -20.1 % opleverde.

Rendement versus markt: 7NS0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.2 % opleverde.

Prijsvolatiliteit

Is 7NS0's price volatile compared to industry and market?
7NS0 volatility
7NS0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 7NS0 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 7NS0 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	9	J. Finley	www.palisadebio.com

Palisade Bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Palisade Bio zich tot de beurswaarde?
7NS0 fundamentele statistieken
Marktkapitalisatie	€3.96m
Inkomsten(TTM)	-€12.57m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is 7NS0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
7NS0 resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$13.50m
Inkomsten	-US$13.50m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-14.42
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 7NS0 op de lange termijn?

Bekijk historische prestaties en vergelijking

7NS0 Overzicht aandelen

Risicoanalyse

Palisade Bio, Inc. Concurrenten

DB:93M1

€105.3m

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

Recent updates

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

New major risk - Market cap size

Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million.

Palisade Bio, Inc. announced that it has received funding

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Palisade Bio, Inc. Announces Executive Changes

Palisade Bio, Inc. Announces Chief Executive Officer Transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022

Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million.

Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio, Inc. announced a financing transaction

Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148

High number of new directors

Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022

Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development

Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

High number of new and inexperienced directors

Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center

Palisade Bio, Inc. announced delayed 10-Q filing

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Palisade Bio, Inc. Samenvatting